CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer, and determine optimal strategies to effectively identify patients harboring these abnormalities.
  • Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
  • Interrogate published research documenting the efficacy of available and investigational oral SERDs for ESR1-mutated ER-positive, HER2-negative metastatic breast cancer progressing on standard endocrine therapy with a CDK4/6 inhibitor in order to optimally integrate these agents into patient care.
  • Evaluate available clinical trial data with oral SERDs in combination with other therapeutic agents for patients with and without ESR1 mutations, and consider the potential role of these regimens.
  • Appreciate the side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients undergoing treatment with this form of therapy.
  • Assess ongoing clinical research evaluating novel applications of oral SERDs for ER-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 3.25 (audio) and 2.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/OralSERDsmBCThinkTank2025/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OralSERDsmBCThinkTank2025/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/OralSERDsmBCThinkTank2025/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OralSERDsmBCThinkTank2025.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Francois-Clement Bidard, MD, PhD
  Professor of Medical Oncology
  Institut Curie
  Paris, France
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foresight Diagnostics, Inatherys, Lilly, Menarini Silicon Biosystems, Novartis, Pfizer Inc, Roche Laboratories Inc, SAGA Diagnostics; Congress Attendance Support: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, MSD, Novartis, Personalis, Pfizer Inc, ProLynx Inc, Roche Laboratories Inc, SAGA Diagnostics, Tempus; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Novartis, Roche Laboratories Inc.
  
  Hope S Rugo, MD
  Director, Women’s Cancers Program
  Division Chief, Breast Medical Oncology
  Professor, Department of Medical Oncology and Therapeutics Research
  City of Hope Comprehensive Cancer Center
  Duarte, California
  Professor Emeritus, UCSF
  
  Advisory Committees: Bristol Myers Squibb, Chugai Pharmaceutical Co Ltd, Napo Pharmaceuticals Inc, Sanofi; Contracted Research (Institutional Research Support): Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc.
  
  Rebecca Shatsky, MD
  Professor of Clinical Medicine
  Breast Medical Oncology Team Leader
  Director of Breast Cancer Clinical Trials
  Director of Inflammatory and Triple Negative Breast Cancer Program
  University of California San Diego
  Moores Cancer Center
  San Diego, California
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Consulting Agreements: Daiichi Sankyo Inc; Contracted Research: Institutional funding (principal investigator for trials) — Alterome Therapeutics, AstraZeneca Pharmaceuticals LP, BriaCell, Gilead Sciences Inc, Hummingbird Bioscience, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, OBI Pharma Inc, OnKure Therapeutics, Regor Therapeutics, Stemline Therapeutics Inc.
  
  Seth Wander, MD, PhD
  Director of Precision Medicine
  Termeer Center for Targeted Therapies
  Director of Translational Research
  Breast Oncology Program
  Massachusetts General Hospital
  Assistant Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hologic Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Stemline Therapeutics Inc.
  
  Release date: October 2025
  Expiration date: October 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.